Découvrez les dernières actualités et naviguez avec le sous-menu.
OCR the company revolutionising the selection of effective drug candidates for cancer, raises €1.25m from Newfund, NFA and the management team in order to accelerate its growth.
OCR emerges as a leading vet CRO in Europe after signing a succession of major contracts.
OCR and Pierre Fabre’s Phase I Clinical Pharmacology Study published in prestigious Clinical Cancer Research journal.
OCR represented at 106th AACR Annual Meeting by Dr. Grégoire Prevost.
OCR and Ecrins Therapeutics initiate €1.9m “Dog to Man” pioneering translational research programme to advance human and vet oncology treatment.
OCR and PRISM announce ground-breaking research collaboration to advance real-time diagnosis using mass spectrometry.
OCR strengthens veterinary and R&D expertise to respond to the needs of the pharmaceutical industry.
